Soonmyung Paik
#161,977
Most Influential Person Now
Researcher
Soonmyung Paik's AcademicInfluence.com Rankings
Soonmyung Paikcomputer-science Degrees
Computer Science
#9396
World Rank
#9870
Historical Rank
Computational Linguistics
#2262
World Rank
#2285
Historical Rank
Machine Learning
#4099
World Rank
#4148
Historical Rank
Artificial Intelligence
#4439
World Rank
#4500
Historical Rank
Download Badge
Computer Science
Soonmyung Paik's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Soonmyung Paik Influential?
(Suggest an Edit or Addition)Soonmyung Paik's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. (2004) (5593)
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
- American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2014) (3308)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006) (2385)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) (1551)
- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. (2008) (1548)
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) (1439)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
- Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer (2018) (1273)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. (2015) (1097)
- Use of archived specimens in evaluation of prognostic and predictive biomarkers. (2009) (954)
- Nanomaterials for theranostics: recent advances and future challenges. (2015) (933)
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2006) (907)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. (1990) (623)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. (2002) (574)
- Development of the 21-gene assay and its application in clinical practice and clinical trials. (2008) (552)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. (2010) (543)
- Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. (2002) (492)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 (1999) (385)
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. (2016) (362)
- Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. (2007) (332)
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. (2013) (327)
- HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. (2000) (322)
- Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. (2003) (313)
- Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. (2010) (277)
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value (2012) (272)
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. (2019) (269)
- Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial (2019) (230)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 (2011) (191)
- Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. (2007) (187)
- Gene-expression-based prognostic assays for breast cancer (2010) (156)
- Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. (2013) (154)
- Gene expression profiling of breast cancer: a new tumor marker. (2005) (152)
- Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. (2016) (149)
- HER2 status and benefit from adjuvant trastuzumab in breast cancer. (2008) (144)
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. (2019) (141)
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. (2015) (131)
- A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes (2010) (129)
- Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. (2013) (121)
- Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). (1989) (118)
- Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. (2011) (113)
- Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. (2015) (107)
- 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy (2017) (103)
- Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer (2005) (102)
- Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (2013) (101)
- Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. (2009) (100)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. (2004) (99)
- Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer (2005) (96)
- Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 (2003) (87)
- Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. (2002) (87)
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. (2020) (85)
- Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. (2003) (82)
- Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial (2017) (81)
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) (2013) (77)
- Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 (2007) (75)
- Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. (2009) (74)
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (74)
- Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. (2014) (73)
- Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials (2008) (72)
- Lower-category benign breast disease and the risk of invasive breast cancer. (2004) (71)
- Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Proje (2016) (67)
- Research issues affecting preoperative systemic therapy for operable breast cancer. (2008) (66)
- Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. (2018) (63)
- Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
- Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). (1986) (61)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. (2010) (60)
- Is gene array testing to be considered routine now? (2011) (59)
- Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. (2013) (58)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (58)
- Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (2014) (58)
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. (2012) (52)
- Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
- Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth (2018) (43)
- Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer (2004) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer (2019) (42)
- Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative (2016) (40)
- Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. (2019) (38)
- Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 (2017) (37)
- CDX 2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer (2016) (37)
- New generation of molecular prognostic and predictive tests for breast cancer. (2007) (34)
- 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology (2018) (32)
- Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. (2012) (30)
- Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype (2017) (30)
- HER2 as a predictor of therapeutic response in breast cancer. (2000) (30)
- Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. (2009) (29)
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. (2019) (29)
- Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer (2020) (28)
- Methods for Gene Expression Profiling in Clinical Trials of Adjuvant Breast Cancer Therapy (2006) (26)
- Colon Cancer Mutation: Prognosis/Prediction–Response (2013) (25)
- Molecular profiling of breast cancer (2006) (25)
- NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (24)
- Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28 (2012) (23)
- Clinical trial methods to discover and validate predictive markers for treatment response in cancer. (2003) (22)
- Reply to E.A. Rakha et al. (2015) (21)
- A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2 (2015) (21)
- Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). (2012) (20)
- PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer (2019) (19)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. (2016) (19)
- Anthracyclines in the treatment of HER2-negative breast cancer. (2008) (19)
- HER-2 and choice of adjuvant chemotherapy in breast cancer. (2001) (19)
- Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer (2018) (18)
- Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. (2018) (18)
- Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology) (2017) (18)
- Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. (2006) (17)
- Genomics of adjuvant therapy for breast cancer. (2011) (17)
- Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer (2020) (17)
- Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma (2015) (17)
- Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. (2020) (16)
- Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. (2009) (16)
- The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. (2008) (14)
- Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck (2020) (14)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (14)
- Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
- Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma (2015) (13)
- Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial (2019) (13)
- Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. (2021) (13)
- Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value (2012) (13)
- Predictive value of microsatellite instability-high remains controversial. (2007) (13)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine (2015) (11)
- Abstract OT2-2-04: A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/− one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NSABP S1207. (2012) (11)
- An ideal prognostic test for estrogen receptor-positive breast cancer? (2008) (11)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (11)
- Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. (2009) (11)
- Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140) (2015) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 (2015) (10)
- Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. (2014) (10)
- registHER: A prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer (2005) (10)
- Incorporating genomics into the cancer clinical trial process. (2001) (10)
- Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer (2020) (10)
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
- Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (2008) (9)
- A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS (2019) (9)
- Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer). (2019) (9)
- Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. (2009) (8)
- Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial. (2021) (8)
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 (2017) (8)
- Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations (2018) (8)
- EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines (2016) (7)
- Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer (2017) (7)
- Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. (2019) (7)
- Genomic profiling of the residual disease of advanced high‐grade serous ovarian cancer after neoadjuvant chemotherapy (2019) (7)
- Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) (2010) (7)
- An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier (2020) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31 (2019) (6)
- Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score (2021) (6)
- NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. (2013) (6)
- Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls. (2015) (6)
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement (2006) (5)
- Molecular assays to predict prognosis of breast cancer. (2007) (5)
- Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. (2010) (5)
- Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer (2017) (4)
- Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). (2015) (4)
- Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer (2021) (4)
- Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (4)
- NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
- Regulation of proliferation and differentiation of normal and malignant breast: new factors and neu paradoxes (1993) (4)
- The concordance between NCCTG's and NSABP's C-myc FISH assays (2008) (4)
- Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma (2020) (4)
- Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28 (2012) (4)
- Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (3)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (3)
- Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) (3)
- Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
- AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencing (2018) (3)
- BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy (2019) (3)
- NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC). (2012) (3)
- Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial (2007) (2)
- The 12-Gene Colon Cancer Recurrence Score (RS) Predicts Recurrence in Stage II and III Colon Cancer Patients Treated with 5FU/LV (FU) and 5FU/LV + Oxaliplatin (FU + OX): Validation in NSABP C07 (2012) (2)
- Abstract P3-10-04: The fully validated NSABP/NRG 8-gene signature which predicted the degree of benefit in the adjuvant setting (B-31 and NCCTG N9831) associates with pCR in the neoadjuvant setting in NSABP clinical trial FB-7 (2019) (2)
- Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy. (2002) (2)
- Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42 (2017) (2)
- Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07. (2016) (2)
- Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution. (2016) (2)
- Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy with or without one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-neu-negative breast cancer: SWOG/NSABP S1207. (2013) (2)
- registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2007) (2)
- Evolving role of pathology in modern oncology (2006) (1)
- DCIS: evidence from radomized trials (2003) (1)
- Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer (2018) (1)
- Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 (2020) (1)
- American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations forimmunohistochemical testing of estrogen andprogesterone receptors in breast cancer (2010) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Abstract 1765: Recurrent fusion of NTRK1 in glioblastoma multiforme. (2013) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Abstract 5012: Mouse-human co-clinical trials demonstrate superior efficacy with combinational approach of BKM120 and erbitux over BKM120 monotherapy in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN) (2017) (1)
- Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. (2011) (1)
- Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 (2019) (1)
- Genomic landscape of extraordinary responses in metastatic breast cancer (2021) (1)
- Molecular basis of steroid and growth factor receptors as prognostic variables in breast cancer (1991) (1)
- P264 Predicting late distant recurrence risk in ER+ breast cancer after five years of tamoxifen (2015) (1)
- 478 Prognostic Significance of pAKT Plus Estrogen Receptor Status in Adjuvant Cytotoxic Treatment of Breast Cancer (2012) (1)
- Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. (2016) (1)
- Abstract 5167: Stem-like colorectal cancer cell lines show response to the ERK1/2 inhibitor, SCH772984, alone and in combination with neratinib (2017) (1)
- DNA mismatch repair deficiency and benefit from adjuvant bevacizumab in NSABP C-08: Molecular profiling results. (2012) (1)
- Methods for gene expression profiling in clinical trials for breast cancer (2005) (0)
- Abstract 5613: PD-1 and TIGIT are major immune checkpoint receptors expressed in breast cancer-infiltrating T cells (2017) (0)
- Tumor stroma percentage (TSP) and intrinsic subtypes in stage II/III colon cancer: NRG Oncology/NSABP C-07 trial. (2019) (0)
- Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2020) (0)
- Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique (2005) (0)
- Prognostic Biomarker in Stage II and Stage III Colon Cancer Permalink (2016) (0)
- Abstract CT129: Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31 (2015) (0)
- Abstract 706: Inflammatory and stem-like colorectal cell lines show differential response to MEK-162 and neratinib in combination (2015) (0)
- Adjuvant Trastuzumab Benefit in Patients Diagnosed With Triple-Positive Breast Cancer (2017) (0)
- Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials (2015) (0)
- Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer (2020) (0)
- Algorithme de profile d'expression et test du pronostic du cancer (2004) (0)
- Abstract P1-07-04: Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52 (2022) (0)
- Machine Learning-Based Mortality Prediction Model for Critically Ill Cancer Patients Admitted to the Intensive Care Unit (CanICU) (2023) (0)
- Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative. (2016) (0)
- Tamoxi fen , Radiat ion Therapy , or Both for Prevent ion of Ips i la tera l Breast Tumor Recurrence Af ter Lumpectomy in Women With Invas ive Breast Cancers of One Cent imeter or Less (2002) (0)
- Abstract P3-08-43: Comprehensive analysis of lymphopenia in large-scaled early and metastatic breast cancer database cohort (2020) (0)
- Session 7. Surgery of breast cancer: Focus on controversies (2011) (0)
- Nanomaterials for Theranostics: Recent Advances and Future Challenges * (0)
- In vitro validation of the immunogenicity of the predicted neoepitopes from high-risk estrogen receptor-positive breast cancer (2021) (0)
- Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers (2011) (0)
- Assays for Gene Amplification (2006) (0)
- Neoadjuvant trials for discovery and validation of predictive markets—a new NSABP clinical trial paradigm (2005) (0)
- Indicateurs moleculaires de pronostic de cancer du sein et prediction de reponse de traitement (2005) (0)
- Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score (2021) (0)
- Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08. (2021) (0)
- Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer (2020) (0)
- Abstract 2711: Graphical method to predict drug response using genomic biomarkers with nonlinear interaction effect (2012) (0)
- Abstract S3-05: Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in NSABP trial B-31 (2015) (0)
- Abstract P6-10-03: The contribution of common genetic variation to breast cancer risk among women receiving tamoxifen or raloxifene within the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 trials (2015) (0)
- Abstract 1037: Comprehensive molecular profiles of gastric cancer patient derived xenograft (PDX) models and its implication in precision cancer medicine (2018) (0)
- Abstract P4-12-28: HER2-related biomarkers in HER2+ breast cancer patients in Asia Pacific (2013) (0)
- Abstract P1-04-10: Association of stromal tumor infiltrating lymphocytes (sTILs) in pretreatment biopsies in different molecular subtypes of HER2+/ER+ breast cancer: Assessment of NRG Oncology/NSABP B-52 (2023) (0)
- Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial. (2022) (0)
- Abstract P3-10-26: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort (2010) (0)
- Abstract A201: Mutation profiling and prognostic value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in colon cancer: Results from NSABP C‐07 (2009) (0)
- Abstract 4727: Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression (2011) (0)
- Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev. (2022) (0)
- Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers (2023) (0)
- molecular prognostic indicators of breast cancer and predicting treatment response (2005) (0)
- Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. (2023) (0)
- Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42 (2022) (0)
- Abstracts reprinted from journal of clinical oncology (2007) (0)
- Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207 (2023) (0)
- registHER: Baseline characteristics of a cohort of HER2-positive metastatic breast cancer (MBC) patients. (2006) (0)
- Abstract C132:Fusobacterium nucleatumin colorectal carcinoma and expression of multiple immune checkpoint molecules on T cells (2019) (0)
- Predicting the likelihood of recurrence of cancer (2004) (0)
- In vitro validation of neoantigen prediction algorithm for developing personalized cancer vaccine therapy (2021) (0)
- A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42 (2019) (0)
- Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41 (2021) (0)
- Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx (2019) (0)
- Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer (2020) (0)
- Gene Expression–Based Predictors of Prognosis and Response to Chemotherapy in Breast Cancer (2020) (0)
- 177PRECURRENCE SCORE AND QUANTITATIVE ER EXPRESSION PREDICTS LATE DISTANT RECURRENCE RISK IN ER+ BC AFTER FIVE YEARS OF TAMOXIFEN. (2014) (0)
- National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer Reply (2015) (0)
- Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and / or Metastatic Squamous Cell Carcinoma of Head and Neck (2015) (0)
- NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (0)
- Inflammatory breast cancer is associated with an increased microvessel density compared with non-inflammatory breast cancer. (2002) (0)
- Prediction de probabilite de la recurrence d'un cancer (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Soonmyung Paik?
Soonmyung Paik is affiliated with the following schools:
